Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Central Line-Associated Thrombus Formation in an Inhibitor Negative Severe Hemophilia A Patient on Emicizumab

Nicholas B George, MD, Alexander Paschke, Katie Scott, MD

Blood (2019) 134 (Supplement_1): 4938.

https://doi.org/10.1182/blood-2019-127105

Published: 2019

Journal Articles

Idiopathic Hemochromatosis Presenting As a Sicca Syndrome. A Case Report and Review of the Literature

Bilawal Ahmed, MD, Beenish Zulfiqar, MD

Blood (2017) 130 (Supplement 1): 4757.

https://doi.org/10.1182/blood.V130.Suppl_1.4757.4757

Published: 2017

Journal Articles

Individualized Prophylaxis with BAY 81-8973: Clinical Experience in an Italian Patient with Severe Hemophilia A

Rita Carlotta Santoro, Piergiorgio Iannaccaro

Blood (2017) 130 (Supplement 1): 4891.

https://doi.org/10.1182/blood.V130.Suppl_1.4891.4891

Published: 2017

Journal Articles

Surgery with Turoctocog Alfa: Efficacy and Safety in Bleeding Prevention During Surgical Procedures - Results From the guardian™ Trials.

Elena Santagostino, MD, PhD, Steven R. Lentz, MD, PhD, Mudi Misgav, MD, Brigitte Brand, MD, Pratima Chowdary, MBBS, FRCP, FRCPath, Aleksander Savic, MD, Yurdanur Kilinc, MD, Edward GD Tuddenham, MBBS, FRCP, FRCPath, PhD, Anders Lindblom, MD, PhD

Blood (2012) 120 (21): 2228.

https://doi.org/10.1182/blood.V120.21.2228.2228

Published: 2012

Journal Articles

Clinical Trial Evaluating DC/AML Fusion Cell Vaccination Alone and in Conjunction with PD-1 Blockade in AML Patients Who Achieve a Chemotherapy-Induced Remission

Blood (2011) 118 (21): 948.

https://doi.org/10.1182/blood.V118.21.948.948

Published: 2011

NARROW

Central Line-Associated Thrombus Formation in an Inhibitor Negative Severe Hemophilia A Patient on Emicizumab

Idiopathic Hemochromatosis Presenting As a Sicca Syndrome. A Case Report and Review of the Literature

Individualized Prophylaxis with BAY 81-8973: Clinical Experience in an Italian Patient with Severe Hemophilia A

Surgery with Turoctocog Alfa: Efficacy and Safety in Bleeding Prevention During Surgical Procedures - Results From the guardian™ Trials.

Clinical Trial Evaluating DC/AML Fusion Cell Vaccination Alone and in Conjunction with PD-1 Blockade in AML Patients Who Achieve a Chemotherapy-Induced Remission

Email alerts

ASH Publications

American Society of Hematology

Central Line-Associated Thrombus Formation in an Inhibitor Negative Severe Hemophilia A Patient on Emicizumab

Idiopathic Hemochromatosis Presenting As a Sicca Syndrome. A Case Report and Review of the Literature

Individualized Prophylaxis with BAY 81-8973: Clinical Experience in an Italian Patient with Severe Hemophilia A

Surgery with Turoctocog Alfa: Efficacy and Safety in Bleeding Prevention During Surgical Procedures - Results From the guardian™ Trials.

Clinical Trial Evaluating DC/AML Fusion Cell Vaccination Alone and in Conjunction with PD-1 Blockade in AML Patients Who Achieve a Chemotherapy-Induced Remission

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only